Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jun;39(6):1253–1258. doi: 10.1128/aac.39.6.1253

Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.

J D Knudsen 1, N Frimodt-Møller 1, F Espersen 1
PMCID: PMC162722  PMID: 7574511

Abstract

The purpose of the study was to investigate the correlation of in vitro activity with the in vivo effect and the pharmacokinetics of penicillin in the treatment of infections with pneumococci with various susceptibilities to penicillin. We used 10 pneumococcal strains for which penicillin MICs ranged from 0.016 to 8 micrograms/ml. Time-kill curve experiments were performed with all strains. We found that the effect of penicillin in vitro is concentration independent, with a maximum effect at two to four times the MIC for penicillin-susceptible as well as penicillin-resistant pneumococci. The mouse peritonitis model with an inoculum of approximately 10(6) CFU, to which mucin was added, resulted in a reproducible lethal infection with the pneumococci. The 50% effective dose was determined for each strain, and we found a highly significant correlation between the log MIC and the log 50% effective dose of penicillin against these strains (P < 0.01). Furthermore, it was shown that the most important pharmacokinetic parameter determining the effect of penicillin in vivo was the time that the concentration of penicillin in serum was greater than the MIC.

Full Text

The Full Text of this article is available as a PDF (274.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Azoulay-Dupuis E., Vallee E., Veber B., Bedos J. P., Bauchet J., Pocidalo J. J. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother. 1992 Dec;36(12):2698–2703. doi: 10.1128/aac.36.12.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bakker-Woudenberg I. A., van den Berg J. C., Fontijne P., Michel M. F. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol. 1984 Apr;3(2):131–135. doi: 10.1007/BF02014330. [DOI] [PubMed] [Google Scholar]
  4. Barry B., Muffat-Joly M., Gehanno P., Pocidalo J. J. Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1993 Aug;37(8):1599–1603. doi: 10.1128/aac.37.8.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Caputo G. M., Appelbaum P. C., Liu H. H. Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features. Arch Intern Med. 1993 Jun 14;153(11):1301–1310. [PubMed] [Google Scholar]
  6. Chesney P. J. The escalating problem of antimicrobial resistance in Streptococcus pneumoniae. Am J Dis Child. 1992 Aug;146(8):912–916. doi: 10.1001/archpedi.1992.02160200034022. [DOI] [PubMed] [Google Scholar]
  7. Craig W. A. Qualitative susceptibility tests versus quantitative MIC tests. Diagn Microbiol Infect Dis. 1993 Mar-Apr;16(3):231–236. doi: 10.1016/0732-8893(93)90115-n. [DOI] [PubMed] [Google Scholar]
  8. Espersen F., Clemmensen I., Rhodes J. M., Jensen K. Human serum and plasma increase mouse mortality in Staphylococcus aureus intraperitoneal infection. Acta Pathol Microbiol Immunol Scand B. 1984 Dec;92(6):305–310. doi: 10.1111/j.1699-0463.1984.tb02838.x. [DOI] [PubMed] [Google Scholar]
  9. Fantin B., Leggett J., Ebert S., Craig W. A. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother. 1991 Jul;35(7):1413–1422. doi: 10.1128/aac.35.7.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fernández Guerrero M. L., Arbol F., Verdejo C., Fernández Roblas R., Soriano F. Treatment of experimental endocarditis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1994 May;38(5):1103–1106. doi: 10.1128/aac.38.5.1103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Frimodt-Møller N., Bentzon M. W., Thomsen V. F. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis. 1986 Sep;154(3):511–517. doi: 10.1093/infdis/154.3.511. [DOI] [PubMed] [Google Scholar]
  12. Frimodt-Møller N., Bentzon M. W., Thomsen V. F. Experimental pneumococcus infection in mice: comparative in vitro and in vivo effect of cefuroxime, cefotaxime and ceftriaxone. Acta Pathol Microbiol Immunol Scand B. 1987 Oct;95(5):261–267. doi: 10.1111/j.1699-0463.1987.tb03123.x. [DOI] [PubMed] [Google Scholar]
  13. Frimodt-Møller N., Sebbesen O., Frølund Thomsen V. The pneumococcus and the mouse protection test: importance of the lag phase in vivo. Chemotherapy. 1983;29(2):128–134. doi: 10.1159/000238186. [DOI] [PubMed] [Google Scholar]
  14. Frimodt-Møller N., Thomsen V. F. The pneumococcus and the mouse-protection test: correlation of in vitro and in vivo activity for beta-lactam antibiotics, vancomycin, erythromycin and gentamicin. Acta Pathol Microbiol Immunol Scand B. 1987 Jun;95(3):159–165. doi: 10.1111/j.1699-0463.1987.tb03106.x. [DOI] [PubMed] [Google Scholar]
  15. Jacobs M. R., Bajaksouzian S., Appelbaum P. C., Bolmström A. Evaluation of the E-Test for susceptibility testing of pneumococci. Diagn Microbiol Infect Dis. 1992 Jul;15(5):473–478. doi: 10.1016/0732-8893(92)90093-9. [DOI] [PubMed] [Google Scholar]
  16. Jacobs M. R. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1992 Jul;15(1):119–127. doi: 10.1093/clinids/15.1.119. [DOI] [PubMed] [Google Scholar]
  17. Jensen K. T., Schønheyder H., Pers C., Thomsen V. F. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources. APMIS. 1992 Jun;100(6):543–552. [PubMed] [Google Scholar]
  18. Jorgensen J. H., Ferraro M. J., McElmeel M. L., Spargo J., Swenson J. M., Tenover F. C. Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test. J Clin Microbiol. 1994 Jan;32(1):159–163. doi: 10.1128/jcm.32.1.159-163.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kapral F. A. Factors involved in experimental staphylococcal peritonitis. Ann N Y Acad Sci. 1965 Jul 23;128(1):259–273. doi: 10.1111/j.1749-6632.1965.tb11643.x. [DOI] [PubMed] [Google Scholar]
  20. Klugman K. P. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990 Apr;3(2):171–196. doi: 10.1128/cmr.3.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Leggett J. E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb;159(2):281–292. doi: 10.1093/infdis/159.2.281. [DOI] [PubMed] [Google Scholar]
  22. Macias E. A., Mason E. O., Jr, Ocera H. Y., LaRocco M. T. Comparison of E test with standard broth microdilution for determining antibiotic susceptibilities of penicillin-resistant strains of Streptococcus pneumoniae. J Clin Microbiol. 1994 Feb;32(2):430–432. doi: 10.1128/jcm.32.2.430-432.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Muñoz R., Coffey T. J., Daniels M., Dowson C. G., Laible G., Casal J., Hakenbeck R., Jacobs M., Musser J. M., Spratt B. G. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis. 1991 Aug;164(2):302–306. doi: 10.1093/infdis/164.2.302. [DOI] [PubMed] [Google Scholar]
  24. Potel G., Chau N. P., Pangon B., Fantin B., Vallois J. M., Faurisson F., Carbon C. Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding. Antimicrob Agents Chemother. 1991 Oct;35(10):2085–2090. doi: 10.1128/aac.35.10.2085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sullivan M. C., Cooper B. W., Nightingale C. H., Quintiliani R., Lawlor M. T. Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model. Antimicrob Agents Chemother. 1993 Feb;37(2):234–239. doi: 10.1128/aac.37.2.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES